15 news items
HC Wainwright & Co. Initiates Coverage On Prime Medicine with Buy Rating, Announces Price Target of $10
PRME
20 May 24
HC Wainwright & Co. analyst Arthur He initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $10.
Citigroup Upgrades Prime Medicine to Buy, Announces $10 Price Target
PRME
16 May 24
Citigroup analyst Samantha Semenkow upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $10 price target.
JP Morgan Maintains Overweight on Prime Medicine, Lowers Price Target to $15
PRME
13 May 24
JP Morgan analyst Eric Joseph maintains Prime Medicine (NASDAQ:PRME) with a Overweight and lowers the price target from $16 to $15.
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
PRME
13 May 24
, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively
Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease
PRME
8 May 24
in vivo with no off-target edits detected IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1
slzgmdl9wlillycemt6r68cm p20kp4ja1fir5rt6
PRME
7 May 24
Jefferies analyst Maury Raycroft assumes Prime Medicine (NASDAQ:PRME) with a Buy rating and lowers Price Target of $15.
g8513j913ko68s2m1ggsba1b0k816upvz2848mj1r a1er2dkin
APVO
ASPN
BFLY
2 May 24
Rob Oliver downgraded Freshworks from Outperform to Neutral and lowered the price target from $28 to $16.
CytomX Therapeutics
uf7e4jtthmxytxnpz 7z4yix6a7i2aeb4ttnlpdlu91i4p3qmchq5002tw9
PRME
1 May 24
, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively
nxs30qcemww37v2x5kx7oovmlhonvbdsquzmdbtt9hg7f55ermzo3d20
ADXN
ALT
ALTM
29 Apr 24
and maintained a $4 price target.
Cyclacel Pharmaceuticals, Inc
vqplsua026fgesmsobz2p0jaqc5kt5d8ahdi3lmx8je1 i6
ALB
ALTM
CGEM
29 Apr 24
from Equal-Weight to Overweight and raised its price target from $21 to $45.
Paramount Global
jzjddxywghwrvpj3ljyaefgtec4m07g0zylp21cz2b9h jg2k
PRME
29 Apr 24
. About PM359PM359, Prime Medicine's first product candidate within its hematology and immunology area of focus, targets
ex7y9fpmnud947tm6 hx8722c0gmduhr5tdd6yxwkwqoipnmqrb2pu6fd33
PRME
23 Apr 24
Wedbush analyst David Nierengarten reiterates Prime Medicine (NASDAQ:PRME) with a Outperform and maintains $12 price target.
m4yagmzb
PRME
3 Apr 24
Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $12.
k8p55brrlqzdwifwf5yhpav2ajhhb2pyz3j2jx5889zhgvqf4154aofv18
PRME
2 Apr 24
Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $12.
v6kdsujz9m58vk3n1w2dyuwv3wfv54g0uzd98q2miuppgy1aofapww
PRME
5 Mar 24
Guggenheim analyst Debjit Chattopadhyay maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $24 to $20.
- Prev
- 1
- Next